ClearValue Team Insights
Stay ahead of the curve by accessing the most recent insights from our expert team. Dive into comprehensive analyses and timely updates covering a spectrum of investment-related news and events.
S&P Continues to Show Strength Near All Time Highs
The S&P closed above $5,500 for the first time in stock market history. Today the S&P continues to climb higher, and SPY has been holding strong above a key white resistance level. Last time SPY managed to briefly rise above this white line before a steep pullback. This time SPY has flipped the white trendline […]Read More
QQQ Rally to $569 Price Target
The stock market is having a historic rally with 8 green candles in the past 9 months. A cup and handle pattern provides a $569 price target over the next few quarters. QQQ is likely to be bullish in July and August so we could continue the streak for a little longer. For now the […]Read More
IWM Continues to Underperform
IWM and small cap stocks continue to show little upside while tech and AI stocks continue to dominate the market. Small caps are significantly discounted, but they are struggling to rally in the short term. These small caps are likely to perform better after rate cuts. For now Mag 7 and tech stocks continue to […]Read More
TSLA Above the Yellow Resistance Line
TSLA has a very strong yellow resistance line with 6 previous rejections at this line. The price is currently above the yellow trendline, and there is a chance of a wick back down. I would monitor the price action carefully here for a potential selloff. If TSLA closes above the yellow trendline by the end […]Read More
U.S. Stock Market Soars to New Highs
The U.S. stock market continues to rally higher while the crypto market has suffered a multi week downtrend. There is now a significant divergence between U.S. stocks and crypto. S&P Holds Above Resistance The S&P has flipped this key resistance level into support, and continues to trend up higher. I’m seeing a lot of bullish […]Read More
AMD Starts to Rally
AMD is trending nicely with its seasonally bullish trend in July. Cheers to those who took this trade, AMD has been one of the top performers during this AI rally. Follow me on social media: https://linktr.ee/realchartchamp
Read MoreDUOL Quick Trade
DUOL is very bullish next week with 100% bullish rate and +13% average gains. The price is testing a key support level around $192.21, and there could be a nice rally to $244.16. The price is unlikely to reach $244.16 within a week, but there could be a nice spike this upcoming week. Entry price: […]Read More
BLFS Quick Trade or Swing Trade
BLFS is seasonally bullish next week with a 86% bullish rate across 7 years and +10%+ average gains. This could be a quick trade or a longer swing trade, the seasonality looks pretty good for the next few weeks. Entry price: $19.44 to $20 Sell targets: Stop loss: $19.30 Follow me on social media: https://linktr.ee/realchartchamp
Read MoreDOCS Quick Trade or Swing Trade
DOCS has been on our list for several weeks in a row. This stock has a lot of swings, and DOCS is seasonally bullish next week with a 100% bullish rate and +10+ average gains. These are my key price levels for DOCS, the price is currently near support at $27.12. Entry price: $26.34 and […]Read More
TSLA is Starting to Rebound
TSLA has built some support around $213 over the past few days, and is starting to form a bullish rebound. I have a white resistance zone as a key target ahead between $264.72 and $271.23. Follow me on social media: https://linktr.ee/realchartchamp
Read MoreDRUG Declines 40% After Yesterday’s Strong Rally
Yesterday DRUG experienced an insane rally with thousands of percent gains. Today DRUG has dropped 40% so far. Some of you have asked me if this is an opportunity to short. I personally wouldn’t trade DRUG in either direction here, but not a bad idea to short if you want to take that risk. There’s […]Read More
NVAX Tumbles by 20% After FDA Clinical Hold
NVAX has declined 20% today after the company said the Food and Drug Administration has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates, following a case of motor neuropathy in a participant in a mid-stage trial. NVAX is currently trading in a white zone that was previously acting as resistance […]Read More